Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen rec… Read more
Olema Pharmaceuticals Inc (OLMA) - Total Liabilities
Latest total liabilities as of September 2025: $44.97 Million USD
Based on the latest financial reports, Olema Pharmaceuticals Inc (OLMA) has total liabilities worth $44.97 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Olema Pharmaceuticals Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Olema Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Olema Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Olema Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Doosan Co Ltd
KO:000157
|
Korea | ₩20.11 Trillion |
|
Beijing Bei Mo Gao Ke Friction Mate
SHE:002985
|
China | CN¥1.13 Billion |
|
Greenland Holdings Corp Ltd
SHG:600606
|
China | CN¥943.05 Billion |
|
Momentum Group Limited
PINK:MMTHF
|
USA | $770.26 Billion |
|
Dehua TB New Decoration Material Co Ltd
SHE:002043
|
China | CN¥2.52 Billion |
|
Burke & Herbert Financial Services Corp. Common Stock
NASDAQ:BHRB
|
USA | $7.07 Billion |
|
SeSa S.p.A.
PINK:SESPF
|
USA | $1.68 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Olema Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Olema Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Olema Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Olema Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $42.02 Million | +82.28% |
| 2023-12-31 | $23.05 Million | +27.36% |
| 2022-12-31 | $18.10 Million | +59.08% |
| 2021-12-31 | $11.38 Million | +148.14% |
| 2020-12-31 | $4.58 Million | -57.25% |
| 2019-12-31 | $10.73 Million | +12.33% |
| 2018-12-31 | $9.55 Million | -- |